|
Q3 FY2026
As of Jun 27, 2026
|
Q2 FY2026
As of Mar 28, 2026
|
Q1 FY2026
As of Dec 27, 2025
|
Q4 FY2025
As of Sep 27, 2025
|
Q3 FY2025
As of Jun 28, 2025
|
Q2 FY2025
As of Mar 29, 2025
|
Q1 FY2025
As of Dec 28, 2024
|
Q4 FY2024
As of Sep 28, 2024
|
Q3 FY2024
As of Jun 29, 2024
|
Q2 FY2024
As of Mar 30, 2024
|
Q1 FY2024
As of Dec 30, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jul 1, 2023
|
Q2 FY2023
As of Apr 1, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 24, 2022
|
Q3 FY2022
As of Jun 25, 2022
|
Q2 FY2022
As of Mar 26, 2022
|
Q1 FY2022
As of Dec 25, 2021
|
Q4 FY2021
As of Sep 25, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS: | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Vendor non-trade receivables | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Non-current assets: | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Total non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY: | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Commercial paper | ||||||||||||||||||||
| Term debt | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-current liabilities: | ||||||||||||||||||||
| Term debt | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Total non-current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Common stock, shares outstanding (in shares) | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Common stock and additional paid-in capital, $0.00001 par value: 50,400,000 shares authorized; 14,608,963 and 14,773,260 shares issued and outstanding, respectively | ||||||||||||||||||||
| Retained earnings/(Accumulated deficit) | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity |
Loading...
